All Drugmakers Enter Medicare Drug Price Talks Amid Lawsuits (1)

Each of the drugmakers selected for the first cycle of Medicare’s drug price negotiation have entered agreements with the agency, the companies told Bloomberg Law.

The latest drugmakers to say yes include Johnson & Johnson, Novartis AG, and Amgen Inc. Other manufacturers include Bristol-Myers Squibb Co., AstraZeneca Plc, and Boehringer Ingelheim, among others who have announced publicly that they will enter the Medicare negotiation program put in place by the Inflation Reduction Act.

“We continue to believe the IRA’s drug price setting provisions are damaging to the innovation ecosystem that delivers transformative therapies and cures ...